Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer

Treatment options for patients with metastatic colorectal cancer (mCRC) are limited. This particularly affects the largest group of patients with RAS mutations, who are considered ineligible for therapy with antiEGFR antibodies. In this liquid biopsy-based study, we performed the first in-depth anal...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Klein-Scory, Susanne, Wahner, Ingo, Maslova, Marina, Al-Sewaidi, Yosef, Pohl, Michael, Mika, Thomas, Ladigan, Swetlana, Schroers, Roland, Baraniskin, Alexander
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7378792/
https://ncbi.nlm.nih.gov/pubmed/32766143
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.01115
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados